Page 2 - Ar T News Today

A SelectScience survey exploring the science and tech at the heart of gene therapy

Imugene Limited (ASX: IMU), a clinical stage immuno-oncology company, highlighted recent progress across the companys immuno-oncology portfolio....

               Gdańsk, Poland – 21 February 2024 – PolTREG S.A. (Warsaw Stock Exchange: PTG), a clinical-stage biotechnology company developing cell...

SAN DIEGO and SUZHOU, China and SHANGHAI, China, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (“Gracell” or the “Company”, NASDAQ:...

Hear about a nascent CRISPR-Cas9 gene editing method used to generate CAR T-cells for next-generation cancer treatment

The Neon was sold as a Chrysler in nearly every other global market and I feel weird just finding this out now.

Stella Vnook, a seasoned veteran in the pharmaceutical industry with extensive experience in senior leadership roles at Catalent, Merck, and Diverse Biotech, has been a prominent figure in the field, particularly in oncology, for over 25 years.

Stella Vnook, a seasoned veteran in the pharmaceutical industry with extensive experience in senior leadership roles at Catalent, Merck, and Diverse Biotech, has been a prominent figure in the field, particularly in oncology, for over 25 years.

Dodge Power Dollars are back, but can’t be applied to Hellcats this time around.

A collaboration to expand autologous CAR-T programs into trials for multiple cancers in a cost-efficient way, has been formed by BioNTech SE and Autolus Therapeutics plc.